These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 32931563)

  • 1. Rapid quantitative screening assay for SARS-CoV-2 neutralizing antibodies using HiBiT-tagged virus-like particles.
    Miyakawa K; Jeremiah SS; Ohtake N; Matsunaga S; Yamaoka Y; Nishi M; Morita T; Saji R; Nishii M; Kimura H; Hasegawa H; Takeuchi I; Ryo A
    J Mol Cell Biol; 2020 Nov; 12(12):987-990. PubMed ID: 32931563
    [No Abstract]   [Full Text] [Related]  

  • 2. Scalable, Micro-Neutralization Assay for Assessment of SARS-CoV-2 (COVID-19) Virus-Neutralizing Antibodies in Human Clinical Samples.
    Bennett RS; Postnikova EN; Liang J; Gross R; Mazur S; Dixit S; Kocher G; Yu S; Georgia-Clark S; Gerhardt D; Cai Y; Marron L; Lukin VV; Holbrook MR
    Viruses; 2021 May; 13(5):. PubMed ID: 34065987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A tissue culture infectious dose-derived protocol for testing of SARS-CoV-2 neutralization of serum antibodies on adherent cells.
    Hasler F; Duda A; Kündig TM; Johansen P
    STAR Protoc; 2021 Dec; 2(4):100824. PubMed ID: 34467223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid in vitro assays for screening neutralizing antibodies and antivirals against SARS-CoV-2.
    Park JG; Oladunni FS; Chiem K; Ye C; Pipenbrink M; Moran T; Walter MR; Kobie J; Martinez-Sobrido L
    J Virol Methods; 2021 Jan; 287():113995. PubMed ID: 33068703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a Rapid Focus Reduction Neutralization Test Assay for Measuring SARS-CoV-2 Neutralizing Antibodies.
    Vanderheiden A; Edara VV; Floyd K; Kauffman RC; Mantus G; Anderson E; Rouphael N; Edupuganti S; Shi PY; Menachery VD; Wrammert J; Suthar MS
    Curr Protoc Immunol; 2020 Dec; 131(1):e116. PubMed ID: 33215858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Novel In-Cell ELISA Assay Allows Rapid and Automated Quantification of SARS-CoV-2 to Analyze Neutralizing Antibodies and Antiviral Compounds.
    Schöler L; Le-Trilling VTK; Eilbrecht M; Mennerich D; Anastasiou OE; Krawczyk A; Herrmann A; Dittmer U; Trilling M
    Front Immunol; 2020; 11():573526. PubMed ID: 33162987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses.
    Schmidt F; Weisblum Y; Muecksch F; Hoffmann HH; Michailidis E; Lorenzi JCC; Mendoza P; Rutkowska M; Bednarski E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Caskey M; Robbiani DF; Nussenzweig MC; Rice CM; Hatziioannou T; Bieniasz PD
    J Exp Med; 2020 Nov; 217(11):. PubMed ID: 32692348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel linear and broadly neutralizing peptide in the SARS-CoV-2 S2 protein for universal vaccine development.
    Li T; Kan Q; Ge J; Wan Z; Yuan M; Huang Y; Xie Q; Yang Y; Shao H; Li X; Ye L; Qin A; Bu Z; Liu P; Ye J
    Cell Mol Immunol; 2021 Nov; 18(11):2563-2565. PubMed ID: 34645942
    [No Abstract]   [Full Text] [Related]  

  • 9. Evaluation of SARS-CoV-2 neutralizing antibodies using a CPE-based colorimetric live virus micro-neutralization assay in human serum samples.
    Manenti A; Maggetti M; Casa E; Martinuzzi D; Torelli A; Trombetta CM; Marchi S; Montomoli E
    J Med Virol; 2020 Oct; 92(10):2096-2104. PubMed ID: 32383254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative analyses of SARS-CoV-2 binding (IgG, IgM, IgA) and neutralizing antibodies from human serum samples.
    Mazzini L; Martinuzzi D; Hyseni I; Benincasa L; Molesti E; Casa E; Lapini G; Piu P; Trombetta CM; Marchi S; Razzano I; Manenti A; Montomoli E
    J Immunol Methods; 2021 Feb; 489():112937. PubMed ID: 33253698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of SARS-CoV-2 neutralizing antibodies using a vesicular stomatitis virus possessing SARS-CoV-2 spike protein.
    Tani H; Kimura M; Tan L; Yoshida Y; Ozawa T; Kishi H; Fukushi S; Saijo M; Sano K; Suzuki T; Kawasuji H; Ueno A; Miyajima Y; Fukui Y; Sakamaki I; Yamamoto Y; Morinaga Y
    Virol J; 2021 Jan; 18(1):16. PubMed ID: 33435994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serosurvey in BNT162b2 vaccine-elicited neutralizing antibodies against authentic B.1, B.1.1.7, B.1.351, B.1.525 and P.1 SARS-CoV-2 variants.
    Zani A; Caccuri F; Messali S; Bonfanti C; Caruso A
    Emerg Microbes Infect; 2021 Dec; 10(1):1241-1243. PubMed ID: 34092181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody response to SARS-CoV-2 in infected patients with different clinical outcome.
    Anichini G; Gandolfo C; Terrosi C; Fabrizi S; Miceli GB; Gori Savellini G; Prathyumnan S; Franchi F; Cusi MG
    J Med Virol; 2021 Apr; 93(4):2548-2552. PubMed ID: 33427302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of neutralizing antibody responses against SARS-CoV-2 in COVID-19 patients.
    Teresa Valenzuela M; Urquidi C; Rodriguez N; Castillo L; Fernández J; Ramírez E
    J Med Virol; 2021 Jul; 93(7):4334-4341. PubMed ID: 33713457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a Purified Viral Preparation for Studies of COVID-19 (SARS-CoV-2) Biology.
    Chepurnov AA; Kazachinskaya EI; Kazachkova EA; Sharshov KA; Kononova YV; Shelemba AA; Alekseev AY; Gulyeva MA; Voevoda MI; Shestopalov AM
    Bull Exp Biol Med; 2021 Nov; 172(1):49-52. PubMed ID: 34787781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VOC 202012/01 Variant Is Effectively Neutralized by Antibodies Produced by Patients Infected before Its Diffusion in Italy.
    Rondinone V; Pace L; Fasanella A; Manzulli V; Parisi A; Capobianchi MR; Ostuni A; Chironna M; Caprioli E; Labonia M; Cipolletta D; Della Rovere I; Serrecchia L; Petruzzi F; Pennuzzi G; Galante D
    Viruses; 2021 Feb; 13(2):. PubMed ID: 33670182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Six-month antibody response to SARS-CoV-2 in healthcare workers assessed by virus neutralization and commercial assays.
    Bal A; Trabaud MA; Fassier JB; Rabilloud M; Saker K; Langlois-Jacques C; Guibert N; Paul A; Alfaiate D; Massardier-Pilonchery A; Pitiot V; Morfin-Sherpa F; Lina B; Pozzetto B; Trouillet-Assant S;
    Clin Microbiol Infect; 2021 Jun; 27(6):933-935. PubMed ID: 33450388
    [No Abstract]   [Full Text] [Related]  

  • 18. Rapid lateral flow tests for the detection of SARS-CoV-2 neutralizing antibodies.
    Wang JJ; Zhang N; Richardson SA; Wu JV
    Expert Rev Mol Diagn; 2021 Apr; 21(4):363-370. PubMed ID: 33840347
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical performances of an ELISA for SARS-CoV-2 antibody assay and correlation with neutralization activity.
    Padoan A; Zuin S; Cosma C; Basso D; Plebani M; Bonfante F
    Clin Chim Acta; 2020 Nov; 510():654-655. PubMed ID: 32818490
    [No Abstract]   [Full Text] [Related]  

  • 20. B careful: Humoral responses and COVID-19 severity.
    Fanous H; Guerrero-Pena A; Pillai A
    Sci Immunol; 2020 Dec; 5(54):. PubMed ID: 33277373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.